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Abstract
Background: There are various methods for predicting human pharmacokinetics. Among these,
a whole body physiologically-based pharmacokinetic (WBPBPK) model is useful because it gives a
mechanistic description. However, WBPBPK models cannot predict human pharmacokinetics with
enough precision. This study was conducted to elucidate the primary reason for poor predictions
by WBPBPK models, and to enable better predictions to be made without reliance on complex
concepts.
Methods: The primary reasons for poor predictions of human pharmacokinetics were investigated
using a generic WBPBPK model that incorporated a single adjusting compartment (SAC), a virtual
organ compartment with physiological parameters that can be adjusted arbitrarily. The blood flow
rate, organ volume, and the steady state tissue-plasma partition coefficient of a SAC were
calculated to fit simulated to observed pharmacokinetics in the rat. The adjusted SAC parameters
were fixed and scaled up to the human using a newly developed equation. Using the scaled-up SAC
parameters, human pharmacokinetics were simulated and each pharmacokinetic parameter was
calculated. These simulated parameters were compared to the observed data. Simulations were
performed to confirm the relationship between the precision of prediction and the number of
tissue compartments, including a SAC.
Results: Increasing the number of tissue compartments led to an improvement of the average-fold
error (AFE) of total body clearances (CLtot) and half-lives (T1/2) calculated from the simulated
human blood concentrations of 14 drugs. The presence of a SAC also improved the AFE values of
a ten-organ model from 6.74 to 1.56 in CLtot, and from 4.74 to 1.48 in T1/2. Moreover, the within-
2-fold errors were improved in all models; incorporating a SAC gave results from 0 to 79% in CLtot,
and from 14 to 93% in T1/2 of the ten-organ model.
Conclusion: By using a SAC in this study, we were able to show that poor prediction resulted
mainly from such physiological factors as organ blood flow rate and organ volume, which were not
satisfactorily accounted for in previous WBPBPK models. The SAC also improved precision in the
prediction of human pharmacokinetics. This finding showed that the methodology of our study may
be useful for functionally reinforcing a WBPBPK model.
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Background
Various methods have been developed for predicting
human pharmacokinetics, including Dedrick's approach,
non-compartment analysis, and an in vitro-in vivo extrap-
olation (IVIVE) approach used for drug discovery.
Dedrick's approach is an animal scaling-up method,
which is used to extrapolate human pharmacokinetic
parameters from at least 2 animal species [1,2]. In con-
trast, the IVIVE approach, which is also used to extrapolate
clinical pharmacokinetic parameters, uses in vitro materi-
als such as hepatocytes and microsomes to scale up to an
actual target pharmacokinetic parameter such as organ
clearance [3,4]. Among these options, two different mod-
els have been used for many years. The compartment
model, which has a long history, is still the preferred
choice because it is easy to apply. However, this approach
consumes considerable resources when an animal scale-
up approach is used, as many animal experiments are
required for proper analysis; also, the range of application
is limited [5]. In contrast, whole body physiologically-
based pharmacokinetic (WBPBPK) models for simulating
human pharmacokinetics [6] enable the time-course of
the tissue concentrations of various drugs to be simulated
using data from only one species. A WBPBPK model can
also be used for pharmacokinetic/pharmacodynamic (PK/
PD) analysis at a target site. However, such models have
not been commonly used because they are complex. Thus,
it would be advantageous to develop a WBPBPK model
based on a simple concept that is easy to implement.
WBPBPK models have been much investigated. They
exhibit comparatively satisfactory precision in predicting
human pharmacokinetics [7,8]. They are generic, consist-
ing of already well-known methods applicable to rational
PK/PD simulation. However, they do not include solu-
tions for correction when the data used as input parame-
ters show considerable divergence (e.g. as a result of
factors associated with in vitro and in vivo studies). There-
fore, improvement in the precision of predictions cannot
be expected from previous models. Recently, several
WBPBPK models have also been analyzed using a single
simplified method [9]. Unfortunately, the more simpli-
fied versions do not account for the complexity of biolog-
ical systems, as mixed models consist of individual organs
as well as multiple organs considered together. Thus, it
has remained difficult to apply PK/PD analysis at the level
of a target organ, although this method can be useful since
it is relatively simple.
It remains desirable to develop a generic, simple, and
more precise WBPBPK model that is useful at the preclin-
ical stage. Although generic WBPBPK models satisfy the
conditions mentioned above (i.e. they can apply to PK/
PD analysis), the ones currently in use are difficult to
apply to the analysis of various compounds owing to poor
predictive precision and the lack of solutions for correc-
tion. However, if these faults could be rectified, the
generic WBPBPK model would be a more useful method.
To improve the precision of prediction, it is important to
use the available experimental data more efficiently. For
example, preclinical in vivo experiments on rats are essen-
tial for Investigating New Drug (IND) applications. Such
data are useful for predicting human pharmacokinetics
using the generic WBPBPK model, even when the findings
are derived from in silico or in vivo experiments [10].
They should ideally be used prior to the initiation of clin-
ical trials by the pharmaceutical industry. However, it is
possible that the aforementioned data are insufficient for
satisfactory prediction, because a more convenient sup-
plementary method for improving the precision of
human pharmacokinetics prediction with only slight
modifications is not currently available.
The aim of the present study was to construct a WBPBPK
model that will enable human pharmacokinetics to be
predicted with high precision using only in vivo data from
rat studies and in vitro data from liver microsomes or
hepatocytes, and will be supplemented by straightforward
mathematical methods devoid of highly complex con-
cepts. We also used the method developed here indirectly
to investigate the potential reasons why the predictions
achieved to date with precursors of the method have been
poor. To these ends, we used the following procedures. 1.
We speculated about the possible causes of poor precision
of prediction and changed part of a generic WBPBPK
model accordingly. 2. We developed a novel method and
deployed it to identify and ameliorate the causes of poor
prediction. The utility of the new method was demon-
strated by comparing the precision with which it predicted
pharmacokinetic parameters to evaluate its validity. 3. We
elucidated the causes of poor precision of prediction using
the developed method. Because this method involves
only physiology-related parameters, it can show whether
any of these parameters contribute to the lack of precision
in prediction. This is the first investigation aimed at
improving the precision of prediction by WBPBPK models
by attempting to elucidate the reasons for the lack of such
precision.
Materials and methods
Experimentation and data collection
Fourteen drugs with various physicochemical properties
were selected for this study. Tolbutamide [11-13] and
diclofenac [12,14-19] were used as acidic drugs. Mida-
zolam [12,20-22] and diazepam [12,23,24] were used as
neutral drugs. Phenytoin [11,12,14,25,26], imipramine
[12,27-30] and lidocaine [12,31-35] were used as basic
drugs. Gatifloxacin [36], grepafloxacin [37-39], gemi-
floxacin [40,41], pazufloxacin [38,42-45], enoxacin
[38,46-48], fleroxacin [36,38,49] and lomefloxacinTheoretical Biology and Medical Modelling 2008, 5:19 http://www.tbiomed.com/content/5/1/19
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[50,51] were used as zwitterionic drugs. Data collected
from the published literature about these drugs are shown
in Table 1. Kp values (steady state tissue-plasma partition
coefficients) were also obtained from the literature and
are described in the reference column of Table 1. Physico-
chemical parameters such as molecular weight (M.W.),
calculated logP (clogP), topological polar surface area
(tPSA) and calculated molecular reflectability (cMR) were
determined using ChemOffice Ultra 9.0 (Cambridge Soft-
ware, USA).
All the observed human data in this study were obtained
from the literature and were used as published or with the
proper corrections. The total plasma clearance was cor-
rected to the total blood clearance using the blood-plasma
concentration ratio for calculations.
Model development
Generic WBPBPK model
The simple WBPBPK model without membrane permea-
tion was used (equations 1–7). This model incorporated
veins (v), arteries (a), lung, pancreas (panc), heart, liver
(h), kidney (r), small intestine (gi), brain, adipose tissue,
muscle and bone, as well as a single adjusting compart-
ment (Figure 1). The well-stirred model was used for mod-
elling each organ and tissue type. The rat Kp values were
used without correction. Organ clearance was used to
describe system clearance. It was assumed that the excret-
ing organs were the liver, kidney and small intestine.
Physiological input parameters (e.g. the blood flow rate in
each organ or tissue [Qi] and the volume of the organ or
tissue [Vi]) were obtained from the literature [52].
A system of three ordinary linear differential equations
was proposed for liver, kidney and small intestine, which
are organs with elimination processes such as metabolism
and excretion of bile and urine. The following equations
were used [7]:
where C is the concentration, Q is the blood flow rate, V
is the volume of tissue or organ, and Kp is the steady-state
tissue-plasma partition coefficient.
Another system of linear ordinary differential equations
was proposed for the lung and other organs, including a
single adjusting compartment, with no elimination proc-
ess. The following equations were used:
dCh
dt
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Table 1: Pharmacokinetic parameters of various compounds used as inputs for each WBPBPK model simulation
Compound Rat Human References
CLtot
(mL/h/kg)
CLh
(mL/h/kg)
CLr
(mL/h/kg)
CLs
(mL/h/kg)
T1/2
(h)
RB
a fB CLtot
(mL/h/kg)
T1/2
(h)
RB
a fB
Tolbutamide 109 109 0 0 1.8 0.75 0.36 24.0 7.0 0.75 0.12 11–13
Diclofenac 1809 1176 633 0 0.14 0.55 0.009 447 1.2 0.55 0.009 12, 14–19
Midazolam 3024 1542 269 1213 0.53 1 0.066 473 2.8 0.80 0.043 12, 20–22
Diazepam 2492 2343 149 0 1.1 1.04 0.13 40.4 32.8 1.04 0.03 12, 23, 24
Phenytoin 1806 1246 181 379 0.37 0.99 0.23 187 13.2 0.61 0.20 11, 12, 14, 25, 26
Imipramine 2544 1649 895 0 3.5 1.67 0.01 424 16.5 1.67 0.14 12, 27–30
Lidocaine 4252 1276 2764 213 0.57 1.27 0.30 938 2.1 0.80 0.81 12, 31–35
Gatifloxacin 1101 341 574 186 1.8 1.07 0.68 252 6.5 1.07 0.75 36
Grepafloxacin 1079 917 151 11 3.4 1.34 0.44 245 11.6 1.1 0.45 37–39
Gemifloxacin 1300 163 599 432 1.6 1 0.57 500 7.0 1.2 0.30 40, 41
Pazufloxacin 970 90 721 159 0.88 1 0.74 384 1.8 1 0.77 38, 42–45
Enoxacin 1794 57 940 797 1.8 0.91 0.71 527 6.0 0.91 0.57 38, 46–48
Fleroxacin 285 57 195 34 2.6 1.29 0.40 120 9.5 1 0.77 36, 38, 49
Lomefloxacin 1243 973 270 0 4.0 1 0.69 252 7.1 1 0.79 50, 51
aRB (blood-plasma concentration ratio) assumed to be 1 when there were no data in the literature.Theoretical Biology and Medical Modelling 2008, 5:19 http://www.tbiomed.com/content/5/1/19
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where i represents the other organ.
Two linear ordinary differential equations were proposed
for veins and arteries, and the following equations were
used:
Pancreas and bone were not incorporated in the 8-organ
model, and the adipose tissue and muscle were omitted
from the 6-organ model.
The system of linear ordinary differential equations
describing the WBPBPK model was solved numerically
using the Runge-Kutta-Gill method [53].
A correction for intrinsic clearance in the liver was per-
formed for acidic, neutral and basic compounds, using the
in vitro intrinsic liver clearance of both rats and humans
[12]. This correction was necessary because of the large
species differences in metabolism. The following equa-
tion was used for scaling up from the rat to the human
model:
In this equation, sf represents a scaling factor, and the
human:rat hepatic blood flow rate ratio was taken as
0.325.
Renal and secretion clearance corrections for the blood
flow were performed for scaling up from a rat model to a
human model because it has been reported that blood
flow rate is useful for correcting some pharmacokinetic
parameters [54-56]:
where CLorg represents clearance in the kidney or small
intestine, and Qj represents the blood flow rate in these
organs.
Single adjusting compartment
A single adjusting compartment (SAC) was incorporated
into the present model as a potential function that can off-
set the lack of predictive precision. The SAC was incorpo-
rated as a newly-developed virtual organ possessing the
same functions as other organs in place of the "rest of the
body" (carcass) previously used in WBPBPK modelling.
However, the physiological parameters of the SAC were
set up so that they could be adjusted arbitrarily. It was
assumed that the lack of precision in simulating human
pharmacokinetics has typically been caused by certain
physiological factors. Thus, to describe the SAC, its blood
flow rate (QSAC), organ/tissue volume (VSAC) and steady-
state tissue-plasma partition coefficient (KpSAC) were
selected as input parameters. The SAC was also described
using the well-stirred model (equation 5). Simulated rat
pharmacokinetics were fitted to the observed pharmacok-
inetics using QSAC, VS and a KpSAC, all of which could be
changed arbitrarily. These SAC values used for fitting were
fixed as data derived from rat studies.
When the QSAC of a rat was transformed to a human value,
the following equation was used:
dCv
dt
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=
⋅
⋅
⎛
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⎞
⎠
⎟ −
⋅ ∑ (6)
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Concept of the SAC-WBPBPK model Figure 1
Concept of the SAC-WBPBPK model. The compart-
ment "other organs" contained brain, muscle, adipose tissue 
and bone. Pancreas and bone were not incorporated in the 
8-organ model, and adipose tissue and muscle were omitted 
from the 6-organ model.Theoretical Biology and Medical Modelling 2008, 5:19 http://www.tbiomed.com/content/5/1/19
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where Qri is the blood flow rate in the isolated organ. P is
a factor that depends on the individual model; P = 15 was
used for this study. This value was fixed after optimising
the 6- and 8-organ model simulations for correcting the
QSAC, rat where the values were lager than the human Qtot.
This value is intrinsically different for each compound,
but was assumed to be constant in order to give the model
generality.
The following equation was used to transform rat to
human VSAC:
Veins and arteries were not incorporated into the total vol-
ume for each organ or tissue in a SAC. In addition, KpSAC,
which was used as a parameter to describe the tissue dis-
tribution of a SAC, was assumed to be the same as the
value obtained from the rat. This method was used as an
alternative compartment in place of the "rest of the body".
The ability to be arbitrary is its main advantage. In con-
trast, the "rest of the body" has only a fixed parameter,
which could be a major cause of poor prediction.
Calculation of pharmacokinetic parameters
In general, the half-life (T1/2) and the total clearance
(CLtot) are used to compare the precision of prediction of
human pharmacokinetics among models [7-9]. Therefore,
we used these parameters for this purpose. The T1/2 was
calculated using equation 12, and kel (the terminal phase
rate constant) was obtained by linear regression analysis
of the log-transformed concentration-time data. The total
area under the blood concentration-time curve (AUCinf)
was obtained according to the following procedure. Blood
AUC0-t values (where t is the time of the last blood concen-
tration collected) were estimated using Simpson's rule
[57], a more reasonable method than the trapezoidal
method for calculating the AUC precisely. AUCt-inf was
estimated by dividing the final blood concentration meas-
ured by the terminal-phase rate constant. AUCinf is the
sum of AUC0-t and AUCt-inf. CLtot was calculated according
to equation 13.
Statistical analysis
The accuracy and precision of the calculated values were
confirmed by considering the ratio of the observed to the
predicted values. Average values were used to confirm
accuracy, and the average-fold error (AFE) [24] and the
within-2-fold error were used to confirm precision. The
AFE was calculated using the following equation:
where N represents the number of data inputs used for the
calculation.
In order to clarify the major cause of poor predictions by
WBPBPK models, we confirmed the correlations between
certain SAC input parameters and various physicochemi-
cal parameters, which were calculated on the basis of the
structures of the selected compounds.
Results
A generic WBPBPK model and the single adjusting com-
partment (SAC)-WBPBPK model were constructed with
parameters that depended on each compound. The preci-
sion of predictions was confirmed for each model. The
influence of the following two factors on the precision of
simulation of human pharmacokinetics was investigated:
the number of organs incorporated and the presence or
absence of a SAC. The human blood concentration of each
compound was simulated using the constructed model.
The half-life (T1/2) and total clearance (CLtot) values were
calculated from the simulated human blood concentra-
tion. Figure 2a–c shows the relationship of the observed
and predicted CLtot and T1/2 values when a SAC was not
incorporated and the number of organs changed. The pre-
dicted values differed widely from the observed values.
No satisfactory improvement in divergence was observed
in spite of the addition of organs. Figure 3a–c shows the
relationship observed when a SAC was incorporated and
the number of organs altered. The predicted values resem-
bled the observed values more closely in the model incor-
porating a SAC than in the models lacking a SAC. The
precision of the simulated values in each model was con-
firmed by comparing the average fold error (AFE) and the
within-2-fold error. These results (Table 2) showed that
the precision of predictions of human T1/2  values
decreased when some organs were removed from the
model, regardless of the incorporation of a SAC. In the
case of CLtot, the SAC-incorporated model yielded highly
precise predictions in each of the three organ-number
models, even the 6-organ model; the within 2-fold error
was 92%. The AFE and within-2-fold error values were
compared to those obtained from previous generic
WBPBPK models and with those obtained by the conven-
tional method for predicting human pharmacokinetics
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(Table 3). The predictions obtained with the SAC-
WBPBPK model were more precise than those yielded by
the other models.
Significant correlations or non-significant trends were
observed between QSAC, the blood flow rate of a SAC
(Table 4), and four physicochemical parameters (tPSA,
clogP, M.W. and cMR). The correlation coefficients
between QSAC and tPSA, clogP, M.W. and cMR were 0.78,
0.57, 0.73 and 0.52, respectively (Figure 4a–d).
Discussion
Investigation of the lack of precision in simulations of 
human pharmacokinetics using the generic WBPBPK 
model
This study was conducted to clarify the main cause of the
poor predictions obtained with the generic WBPBPK
model and to enable a model to be constructed that could
address this problem easily. We initially attempted to elu-
cidate the divergence in the precision of predictions with
the number of organs investigated, i.e. in the 6-, 8- and 10-
organ models. Poor precision and discrepancies may be
related to one or more of the following: active versus pas-
sive transportation systems, species differences in metab-
olism, and physiological factors such as blood flow rate,
Correlation between the observed and simulated pharmacokinetic parameters predicted without a SAC Figure 2
Correlation between the observed and simulated pharmacokinetic parameters predicted without a SAC. (a) 
Six-organ model without a SAC, (b) 8-organ model without a SAC, (c) 10-organ model without a SAC. The solid line repre-
sents unity, whereas the dashed lines represent the 2-fold prediction error.
Correlation between the observed and simulated pharmacokinetic parameters predicted with a SAC Figure 3
Correlation between the observed and simulated pharmacokinetic parameters predicted with a SAC. (a) Six-
organ model with a SAC, (b) 8-organ model with a SAC, (c) 10-organ model with a SAC. The solid line represents unity, 
whereas the dashed lines represent the 2-fold prediction error.Theoretical Biology and Medical Modelling 2008, 5:19 http://www.tbiomed.com/content/5/1/19
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tissue volume and the number of organs involved. Other
factors could also be involved. The results of this series are
shown in Figure 2: increasing the number of organs in the
model improved the precision of prediction. These results
indicate that failure to account for particular physiological
factors may contribute to the poor predicted values from
the generic WBPBPK model.
On the basis of the present findings, we inferred that not
only species differences in active transportation systems,
metabolism, etc., but also failure to account for the phys-
iological parameters of each individual and each species,
were responsible for the poor predicted values by previous
WBPBPK models. Therefore, the precision with which
human pharmacokinetics were predicted was examined
by adding a single adjusting compartment (SAC), a newly
developed virtual organ that could be expected to improve
the precision of predictions if added to the generic
WBPBPK model. The results are shown in Figure 3. Fitting
of the simulated to the observed rat pharmacokinetics
before scaling up to the human was successful and the AFE
values of T1/2 and CLtot were lower than 1.1 for almost all
compounds. These findings supported our initial assump-
tions, because the improvement in precision observed
with the model incorporating the SAC implicated the pre-
vious failure to account for blood flow rate, tissue volume
and tissue distribution.
The parameters for elucidating the precision of prediction
were calculated (Table 2): the AFEs of CLtot and T1/2 were
greatly improved by incorporating a SAC into the 10-
organ model. If the only major cause of poor predictive
precision had been differences in the active transportation
systems of different species, then it would not have been
possible to correct for differences in predictive precision.
However, inclusion of a SAC in the model corrected for
the divergence resulting from active transportation sys-
tems and metabolism, provided that no species differ-
ences were involved. These findings did not contradict the
assumptions made for the present series, because use of
actual hepatic clearance values did not improve the preci-
sion of predictions. It is therefore reasonable to conclude
that the poor predictive value of the previous methods is
due to their failure to account for physiological factors.
The predictions of CLtot were less precise for tolbutamide,
diclofenac, diazepam, grepafloxacin and lomefloxacin
than for the other compounds tested, even when a SAC
Table 2: Human pharmacokinetic prediction results for 14 compounds
Parameter Group T1/2 CLtot
6 organs 8 organs 10 organs 6 organs 8 organs 10 organs
+- +- +- +- +- +-
AFE acidic 5.45 38.7 2.26 16.6 1.36 13.5 1.39 305 1.07 26.5 2.56 14.7
neutral 3.58 36.6 2.97 2.12 1.64 2.25 4.01 68.5 1.47 14.8 1.38 10.8
basic 4.13 36.8 1.85 7.48 1.76 6.28 1.34 24.4 1.62 5.64 1.10 4.37
zwitterionic 2.80 14.4 1.41 5.10 1.36 3.85 1.40 33.3 1.48 7.40 1.63 5.67
AFE Overall 3.35 23.2 1.75 5.78 1.48 4.74 1.63 47.4 1.47 9.24 1.56 6.74
within-2-fold (%) 0 0 62 14 93 14 92 0 92 0 79 0
+: WBPBPK model with SAC, -: WBPBPK model without SAC.
Table 3: AFE values and within-2-fold errors from the present study and previous studies
Method n AFE Within-2-fold error (%)
T1/2 CLtot T1/2 CLtot
Present work SAC-WBPBPK 14 1.5 1.6 93 79
generic WBPBPK 197) 2.2 2.7 71 71
19 or 268) 1.5 1.1 69 74
Previous work in silico61) 18 N/A 2.8 N/A 50
animal scale-up 191) 2.4 3.4 53 37
1862) N/A 2.5 N/A 50
N/A: not available.Theoretical Biology and Medical Modelling 2008, 5:19 http://www.tbiomed.com/content/5/1/19
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was incorporated into the 10-organ model. The diver-
gence of prediction for the two acidic drugs is thought to
have been caused by drug binding to plasma proteins, i.e.
acidic drugs have a high affinity for plasma albumin,
which leads to a lower contribution to tissue distribution.
Consequently, most of the total pharmacokinetics of a
drug can be described by a SAC and a clearance equation,
together with a scaling-up equation to adjust for the
results obtained from rats. However, a SAC acts only in a
supporting role. The scaling-up equation also acts only in
a supporting role. Therefore, the precision of prediction
for the two acidic drugs tested here might have been worse
than that for the other drugs. Specifically, in order to
obtain precise predictions, the tissue distribution must
have a large influence on the model.
Diazepam, a drug for which predictions show considera-
ble divergence in precision, is known to be a substrate of
human MDR1 [58]. Moreover, grepafloxacin is known to
be a substrate of human MRP1 and rat Mrp2 [59,60].
However, there are no data regarding the contribution of
rat Mdr1 to diazepam pharmacokinetics or of rat Mrp1
and human MRP2 in the case of grepafloxacin. In addi-
tion, the differences between observed and predicted val-
ues were smaller than those obtained when no SAC was
incorporated. Previously reported findings, taken together
with the results of the present study, indicate the involve-
ment of both an active transportation system and species
differences. However, these factors play only a minor role
in the predictive precision of the generic WBPBPK model.
Table 3 compares the predictive precision of the SAC-
WBPBPK model with previous methods. The best within-
2-fold error for predicting human T1/2 values was achieved
with the 10-organ model with a SAC, and the results were
even better for CLtot. Regardless of the AFE values associ-
ated with each of the previous methods (2 in both cases),
the values for T1/2 and CLtot in the SAC-WBPBPK model
showed more precise predictions; both were approxi-
mately 1.5.
In summary, this series revealed that a major factor lead-
ing to the poor precision observed with the generic
WBPBPK model was the failure to account for human
physiological parameters. The precision of a generic
WBPBPK model was improved by incorporating a SAC,
which included such physiological parameters. The results
also indicated that the SAC-WBPBPK model will be more
useful than previous WBPBPK models for predicting
human pharmacokinetics, particularly in cases when pre-
dictions are made with data obtained before the onset of
clinical trials.
Indirect investigation of the lack of precision of simulations 
of human pharmacokinetics using SAC-related parameters
The input parameters for the SAC in this study were useful
not only in terms of fitting the data to rat pharmacokinet-
ics, but also for investigating factors that were missing
from previous models. Initially, it was confirmed that
QSAC, VSAC and KpSAC each correlated with various physic-
ochemical parameters (Table 4). Significant correlations
were confirmed between QSAC and three physicochemical
parameters (topological polar surface area (tPSA), molec-
ular weight (M.W.), and calculated logP (clogP)) and a
non-significant trend was observed between QSAC and cal-
culated molecular reflectability (cMR) (Figure 4). In par-
Table 4: Values of QSAC, VSAC, KpSAC, and various physicochemical parameters
Compound SAC input parameter Physicochemical parameter acidic/neutral/basic/zwitterionic
QV K p V K p a M.W. clogP cMR tPSA
Tolbutamide 2850 330 0.5 165 270 2.5 7.1 93 acidic
Diclofenac 3120 300 0.3 90 296 4.7 7.7 59 acidic
Midazolam 3400 500 1 500 326 3.2 9.1 25 neutral
Diazepam 3130 380 2 760 285 3.2 8.1 36 neutral
Phenytoin 3120 5 0.3 1.5 252 2.1 7.2 70 basic
Imipramine 3120 790 8 6320 280 5.0 9.0 5 basic
Lidocaine 3670 500 2 1000 234 2.0 7.2 38 basic
Gatifloxacin 2830 800 1 800 375 -0.69 9.8 101 zwitterionic
Grepafloxacin 2810 300 1 300 359 -0.13 9.6 87 zwitterionic
Gemifloxacin 2470 100 1 100 389 -0.89 9.9 133 zwitterionic
Pazufloxacin 2920 430 1 430 318 -0.87 8.0 108 zwitterionic
Enoxacin 2970 455 5 2275 320 -1.8 8.2 98 zwitterionic
Fleroxacin 2840 100 1 100 369 -0.65 8.9 77 zwitterionic
Lomefloxacin 2870 650 6 3900 351 -0.30 8.9 87 zwitterionic
aVKp represents the product of V and Kp.Theoretical Biology and Medical Modelling 2008, 5:19 http://www.tbiomed.com/content/5/1/19
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ticular, for the correlations between QSAC and tPSA, a
negative slope below the 0.1% significance criterion was
observed. Generally, compounds with larger tPSA values
are known to permeate the cell membrane with more dif-
ficulty. The finding of large QSAC values indicated that the
previous WBPBPK model does not take sufficient account
of organs with high blood flow rates. On the other hand,
small QSAC values indicate that the previous model was
unable to account for organs with low blood flow rates.
The incorporation of a SAC in the model improved this
issue. The negative-slope correlation between QSAC and
tPSA indicated the following: a compound with a low
tPSA value (i.e. a compound that easily permeates the cell
membrane and is therefore readily distributed among tis-
sues) does not account for the factor of relative blood flow
rate. Thus, high blood flow rates could affect the pharma-
cokinetics of such a compound because cell membrane
permeation is not a major factor. Accordingly, it is reason-
able to assume that the physiological factor of blood flow
rate, such as blood flow-rate limitation, is related to the
outcomes obtained from models. In contrast, for com-
pounds associated with large tPSA values, membrane per-
meability contributes more than blood flow rate because
permeability is low. The problem caused by a large QSAC
(small tPSA) could be resolved by incorporating a mem-
brane permeation process into the WBPBPK model. How-
ever, the problem caused by a small QSAC (large tPSA)
cannot be resolved easily: it is difficult to choose an ade-
quate blood flow rate for each model because of variation
among individuals. This factor could be the cause of poor
predictions for large QSAC drugs. Therefore, we should
keep these points in mind when we perform a proper
human pharmacokinetics simulation. In short, previous
models did not sufficiently account for the relationship
between physiological factors and the unique distribution
that is caused by an individual compound's physicochem-
ical properties. Moreover, adding considerations such as a
permeation process and individual differences in blood
Correlation of QSAC with physicochemical parameters Figure 4
Correlation of QSAC with physicochemical parameters. (a) tPSA, (b) clogP, (c) M.W., (d) cMR. The solid lines represent 
regression.Theoretical Biology and Medical Modelling 2008, 5:19 http://www.tbiomed.com/content/5/1/19
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flow rate for constructing a generic WBPBPK model could
improve the precision of prediction.
The significant correlations that we found between clogP
and QSAC are also considered reasonable, as was the case
with tPSA, because when a drug is more lipophilic, its
ability to permeate the cell membrane increases, resulting
in a smooth distribution to certain tissues. Moreover, this
factor is not related to the presence of an active transpor-
tation system. However, the simple incorporation of
organs did not account for a precise system, because drug
metabolism contributes more when lipophilicity
increases. On the other hand, the present findings indicate
that differences in active transportation systems and
metabolism between species did not play a major role in
the model's predictions; the improvement in predictive
precision when correcting for physiological factors by
incorporating a SAC played a larger role. These conclu-
sions were supported by the correlation between QSAC and
M.W., and by the tendency of QSAC and cMR to reflect
molecular size. QSAC and cMR showed no significant cor-
relations. However, the bias of cMR values of selected
compounds in this study could explain why no significant
correlations were found. The correlation between QSAC
and cMR could be significant, provided the number of test
compounds was increased. These results indicate that
physiological limitations such as blood flow and mem-
brane permeability were involved in improving the pre-
dictive precision of the WBPBPK model. Furthermore,
such physiological limitations were not accounted for suf-
ficiently in previous WBPBPK models.
No significant correlations were observed between VSAC or
KpSAC  and the physicochemical parameters. However,
VSAC and KpSAC tended to overestimate T1/2 as the values
increased (data not shown). Moreover, the tendency
toward overestimation was especially marked when the
product of VSAC and KpSAC, which represented the degree
of tissue distribution, was considered. These results indi-
cate that the SAC was incorporated into this WBPBPK
model as an organ with relatively slow drug transporta-
tion and slow drug elimination. Therefore, estimates of
T1/2 tended to be longer when more of the drug is distrib-
uted to a SAC. With regard to the generic WBPBPK model
without a SAC, the precision of prediction of T1/2 was rel-
atively good. However, the prediction of CLtot showed low
precision. From these results, it is possible that the volume
of distribution (Vd) value was not accurately predicted.
This assumption indicates that the related factors VSAC and
KpSAC in the SAC-WBPBPK model were not present in the
previous generic WBPBPK model because, fundamentally,
Vd is predicted using organ volumes and the Kp value of
each organ. In the present study, the Kp value was not cor-
rected by the blood free fraction (fB) in rat or human when
the model was constructed. Therefore, the actual Kp val-
ues for humans were different from the experimental val-
ues for the rat, which were used in the present study.
Moreover, inter-individual differences in organ volume
are not considered in the generic WBPBPK model. Accord-
ingly, organ volume as a physiological parameter should
have been accounted for in more detail, including the
inter-individual variability of the data set, as well as drug-
specific parameters such as Kp values.
The addition of a SAC, such as that developed for this
study, to various generic WBPBPK models may enhance
the precision of human pharmacokinetics simulations.
This approach may also facilitate with the handling of cer-
tain species differences (e.g. intrinsic clearance) because
the SAC can be used as the "rest of the body (carcass)", i.e.
as a non-specific compartment. Furthermore, this
approach did not require arbitrary alterations of the actual
experimental data, which distinguishes it from methods
in which the observed data must be altered to fit the ani-
mal (rat) findings. Thus, the present approach is a more
rational methodology for prediction. In this regard, we
will discuss the concept underlying the model presented
here. Dedrick's animal scaling-up is an empirical
approach. In contrast, a WBPBPK model entails a mecha-
nistic approach. However, the generic WBPBPK model,
which has been used at the preclinical stage, contains
empirical factors such as Kp values, and a clearance pre-
diction method for scaling up to the human. Moreover, if
membrane permeation processes are incorporated into
the model, we have to rely on empirical methods to scale
up to human permeation rate constants. Nevertheless, the
generic WBPBPK model is applicable for predicting
human pharmacokinetics. That is because almost all parts
of this system consist of actual human physiological
parameters and are linked mechanistically. Therefore, the
WBPBPK approach can elucidate kinetics in organs and is
applicable for a variety of uses. The SAC approach is a
hybrid of an empirical and a mechanistic approach. Using
a SAC, we found that the primary cause of poor prediction
was a failure to consider physiological systems. Therefore,
a SAC approach is compatible with a mechanistic
approach because it complements previous problems. On
the other hand, a SAC is not just described as a physiolog-
ical system. In this context, it is more empirical than the
generic WBPBPK model used previously. However,
despite including an empirical factor, the SAC-WBPBPK
model is more rational than the previous generic WBPBPK
models. Moreover, our model addresses the cause of poor
prediction in previous generic models, and does not need
to manipulate observed experimental values to adjust to
rat pharmacokinetics.
Some limitations are associated with the addition of a
SAC. In this study, tolbutamide kinetics could only be
simulated in a 10-organ model. If no upper or lower limitsTheoretical Biology and Medical Modelling 2008, 5:19 http://www.tbiomed.com/content/5/1/19
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could be set as input parameters for a SAC, then the model
would be unable to deal adequately with outliers. This
problem has not yet been resolved, even when corrections
were made using a scaling-up equation for human QSAC.
This matter will require further study.
Conclusion
Incorporation of a SAC into a generic WBPBPK model, as
performed in this study, significantly improved the preci-
sion of predictions of human pharmacokinetics. For the
first time, failure to account for certain physiological
parameters was identified as a major problem in previous
generic WBPBPK models, in addition to confounders such
as species differences in terms of metabolism and the pres-
ence/absence of active transportation systems (i.e. trans-
porters). Moreover, the SAC-WBPBPK model performed
better than all previous methods in terms of precision of
prediction. Moreover, this newly developed model entails
a simpler and more straightforward methodology than
older models. It is likely that the present model will be
useful not only for predicting clinical pharmacokinetics,
but also for analyzing PBPK/PD at the preclinical stage in
simulations of drug efficacy.
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